Green and direct functionalization of poly (ethylene glycol) grafted polymers onto single walled carbon nanotubes: Effective nanocarrier for doxorubicin delivery

Publication date: 25 March 2020Source: Journal of Industrial and Engineering Chemistry, Volume 83Author(s): Xuan Thang Cao, Maheshkumar Prakash Patil, Quoc Thang Phan, Cuong M.Q. Le, Byung-Hyun Ahn, Gun-Do Kim, Kwon Taek LimAbstractThis paper reports a green and direct functionalization of poly(ethylene glycol)-graft-[furfuryl-graft-(poly(styrene-alt-maleic anhydride))] (PEG-PSMF) on the surface of single walled carbon nanotubes (SWCNTs) in aqueous media through Diels-Alder (DA) click reaction. Firstly, novel PEG grafted, furfuryl functionalized copolymers were prepared by RAFT polymerization followed by ring opening reactions. The functional copolymer was simply grafted on SWCNTs by DA reaction at room temperature under ultrasonication. The resulting hybrid materials were characterized by 1H NMR, GPC, UV–vis, FT-IR, TGA, TEM, and DLS. The hybrid materials possessed a high drug loading capacity (DLC) of doxorubicin (DOX), which could reach up to 279.9 wt.% of DLC. Moreover, in vitro drug release profiles showed that drug release rate at pH 5.5 under an acidic condition of tumor cell microenvironment was much higher than at pH 7.4 of the physiological condition. MTT assays demonstrated that the hybrid materials did not have any practical cytotoxicity against the normal HEK293 cell line, while drug loaded hybrids displayed a high antitumor activity towards HeLa cancer cells. This strategy offers a promising SWCNT-based drug carrier for tumor-targeted chemotherapy.
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research

Related Links:

Publication date: Available online 19 February 2020Source: Molecular and Cellular EndocrinologyAuthor(s): Tenghua Yu, Hong Cheng, Zhijuan Ding, Zhiliang Wang, Lixia Zhou, Peng Zhao, Shengxing Tan, Xue Xu, Xianming Huang, Manran Liu, Meixi Peng, Yu-an QiuAbstractRescue chemotherapy is usually the preferred treatment for patients with advanced estrogen receptor-positive (ER+) breast cancer with endocrinotherapy resistance. However, these patients often simultaneously show a poor response to cytotoxic drugs, and thus the detailed mechanism of this resistance needs to be further investigated. Our previous research indicated th...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Conclusion EORTC criteria and PERCIST had early predictive value to long-term outcome, but moderate value for pCR. Furthermore, PERCIST might show more potential than the EORTC criteria and conventional PET-based parameters to predict prognosis in breast cancer patients following two cycles of neoadjuvant chemotherapy. Video abstract: see http://links.lww.com/NMC/A162.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
A patient with breast cancer at risk of infertility from adjuvant chemotherapy has given birth 5 years after having immature oocytes removed, matured in the laboratory, and then frozen.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
This article reviews current data and ongoing research on atezolizumab for the treatment of breast cancer. Results of atezolizumab monotherapy trials in the context of other early immune checkpoint blockade trials in breast cancer are discussed as well as data from combination clinical trials with chemotherapy in both early stage and metastatic breast cancer. We focus on the safety and efficacy analyses from the phase III IMpassion trial that led to FDA and EMA approval of atezolizumab and nab-paclitaxel in patients whose tumor tested positive for PD-L1 by the Ventana SP142 companion diagnostic immunohistochemical assay.Ex...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Graphical summary ofl‐asparaginase. Abstractl‐Asparaginase (E.C.3.5.1.1.) is a vital enzyme that hydrolyzesl‐asparagine tol‐aspartic acid and ammonia. This property ofl‐asparaginase inhibits the protein synthesis in cancer cells, makingl‐asparaginase a mainstay of pediatric chemotherapy practices to treat acute lymphoblastic leukemia (ALL) patients.l‐Asparaginase is also recognized as one of the important food processing agent. The removal of asparagine byl‐asparaginase leads to the reduction of acrylamide formation in fried food items.l‐Asparaginase is produced by various organisms including animals, pla...
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Review Article Source Type: research
Authors: Meunier L, Larrey D Abstract Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as "CASH" for "Chemotherapy-induced Acute Steatohepatitis". The mechanism of toxicity is essentially based on mitochondrial toxicity. These lesions are chronic and often reversible when the treatment is stopped. Contrib...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanc ed non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing. The FDA is expected to make a decision on approval by June 19, 2020.“In the IMpower110 study, Tecen...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
In this study, we evaluated the efficacy of anlotinib as third ‐ or further‐line treatment for patient with different histological types of NSCLC. In the ALTER0303 trial, 336 patients had the histological subtype of adenocarcinoma (ACC), 86 patients had the histological subtype of squamous cell carcinoma (SCC), and 15 patients had another subtype. Our findi ngs suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients. AbstractBackgroundAnlotinib showed significant survival benefits in advanced non ‐small cell lung cancer (NSCLC) patients as a thir...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Contributors : Stephen N Housley ; Paul Nardelli ; Dario Carrasco ; Lilya V Matyunina ; Mengnan Zhang ; John F McDonald ; Tim C CopeSeries Type : Expression profiling by arrayOrganism : Rattus norvegicusNeurological disorders induced by chemotherapy, including pain and other debilitating sensory conditions correlate with alterations in diverse systemic, cellular, and molecular processes. Chemotherapeutic agents variously induce inflammatory responses, metabolic disorders and associated gene expression changes, all of which have the capacity to impact sensory function . Early evidence of independent effects by cancer alone ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Rattus norvegicus Source Type: research
AbstractFungating breast cancer (FBC) is a rare entity in developed nations. But this occurrence is not uncommon in our country. The aim of this study was to review clinico-pathologic profile and outcomes of FBC in a developing country. This retrospective study consisted of patients with FBC managed at our institute (Jan 2005 –Dec 2015). Clinico-pathologic profile, management details, and outcomes were analyzed. The Kaplan-Meier method was used to determine overall survival (OS). Log-rank test was performed to compare survival in various subgroups. Seventy-nine patients were detected to have FBC constituting 3.3% of ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Nanotechnology